T ranscatheter aortic valve replacement (TAVR) is now well-established as the standard of care for patients with severe symptomatic aortic stenosis who are deemed inoperable, 1 and is seen as an alternative treatment option to surgical aortic valve replacement (SAVR) in a subset of patients with high postoperative mortality. 2 The native valve is typically not removed but instead crushed by the superimposed bioprosthesis, which can result in an incomplete seal of the bioprosthetic valve and aortic annulus, with subsequent occurrence of paravalvular leak (PVL). Two types of Transcatheter Heart Valves (THV) that have been widely used, the balloon-expandable Edwards valve (Cribier-Edwards, Edwards SAPIEN and Edwards SAPIEN XT) by Edwards Lifesciences, and the selfexpandable CoreValve by Medtronic, have been described in detail elsewhere. 3, 4 Despite the evolving technology of transcatheter valves, PVL post-TAVR is common, with a wide range of reported incidences (Table 1) . Most importantly, PVL has been associated with increased short-and long-term mortality post-TAVR, and is seen as a barrier to more widespread use of this promising technique. [5] [6] [7] [8] [9] [10] [11] [12] [13] This article describes the incidence, causes, and predictors of PVL, as well as its impact on clinical outcomes. Methods of prevention, diagnosis, and treatment of PVL are also reviewed.
Definition and Incidence
Aortic regurgitation is characterized as either central or paravalvular. Pathological central regurgitation occurs in diseased native valves or damaged prosthetic valves, whereas minor central regurgitation is often a physiological feature of some bioprosthetic valves by virtue of their design. On the other hand, PVL is a complication only of aortic valve prostheses and occurs more commonly post-TAVR ( Figure 1 ) than after SAVR.
Various multicenter registries and trials have reported data on incidence of PVL post-TAVR at different time points (Table 1 ). The overall incidence of PVL post-TAVR ranges between 50% and 85%, which is significantly higher than what has been observed in SAVR, reported between 1% and 47.6%, with only 4.2% consisting of more than mild PVL. 14 Although the majority of post-TAVR PVL is mild (7.8-40 .8%), moderate (5-37.9%) and severe (0.5-13.6%) PVL occur frequently. 1, 2, 6, 8, 10, 11, 13, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] The largest meta-analysis of TAVR outcomes estimates the incidence of residual moderate or severe aortic regurgitation after TAVR to be 7.4%. 27 The UK TAVR registry suggests moderate-severe PVL occurred more commonly with CoreValve implants (17.3%, versus 9.6% with the Edwards implants). 13 This finding has not been replicated in other studies. One study by Ewe et al 21 did not find a statistically significant difference in incidence of PVL between transfemoral and transapical TAVR at 30 days and 6 months. The wide range of PVL incidence reported is not surprising and is likely a result of the lack of standardization across centers in the TAVR technique, differences in operator experience, types and sizes of valves used, in addition to the different imaging modalities used and challenges in grading PVL. Unbehaun et al 6 used a modified TAVR procedure after which no patient had severe PVL and only 2 had moderate PVL, of a relatively large cohort of 358 patients.
It is unclear whether PVL progresses in severity with time. The studies reporting the rate of PVL for multiple follow-up time points show decreasing incidences of moderate-severe PVL. Although the decrease could be attributed to the death of patients with higher-grade PVL who are at higher mortality risk, a reduction of severity from moderate to mild may also relate to geometric remodeling of the annulus 2, 5, 20, 21 (Table 1) . Rates of mild PVL generally remained stable; there was no evidence of an increase in PVL over time.
Clinical Impact of Paravalvular Leak
Despite the difficulties in accurately characterizing PVL, the wide range of incidences reported, and the relative short period of follow-up, its impact on short-and longterm mortality has been consistently reported across studies (Table 2) . Data from a large cohort of 3201 SAVR patients with a mean follow-up of 4.5±3.4 years confirm that patients with moderate-severe aortic regurgitation (AR>1/4) had lower survival at 1, 5, and 10 years (91.4 versus 96.7%, 77.5 versus 82.4%, and 44.1 versus 54.5%; P<0.01).
14 Other data on clinical outcomes related to PVL extend from the postoperative period to up to 2 years. Moderate-severe PVL is an independent predictor of mortality in the postoperative period to 30 days, at 1 year, and at 2 years [5] [6] [7] [8] [9] [10] [11] 13 (Table  2) . Recently, Kodali et al from the Placement of AoRTic Table 2 ).
Causes and Predictors of Paravalvular Regurgitation
During SAVR the positioning of the prosthesis is performed under direct anatomic observation, allowing excision of the calcified valve, followed by optimal placement and alignment of the prosthetic valve within the aortic annulus. The minimally invasive nature of TAVR precludes removal of the heavily calcified native valve and direct observation of the annulus. It entails using preprocedural imaging to estimate the size of the aortic root, and indirectly implanting a circular bioprosthesis in a dynamic, oval-shaped aortic annulus. The technique relies on fluoroscopy and intraprocedural echocardiography for positioning. Thus, it is not surprising to expect a higher frequency of PVL in TAVR as a result of the risks of inappropriate sizing of the prosthesis, its malpositioning, and the hindrance of the old calcified valve (Table 3) . The diameter of the aortic annulus is measured before and during the procedure to determine the choice and size of the THV. To assess valve-annulus congruence, a cover index integrating aortic annulus diameter (A) and prosthetic diameter (P; 100×[A−P]/P) was used. Moderate-severe regurgitation was not seen with a cover index >8% in this study of 74 patients. These findings were reproducible in a study using intraprocedural 3D tranesesophageal echocardiography (TEE) in addition to transthoracic echocardiography (TTE) to evaluate the THV. 18 In another prospective study, annulusprosthesis mismatch was defined as a native annulus diameter larger than normal on label diameter limit for the prosthesis and was associated with higher grade PVL. 28 Larger aortic annulus size measured by MRI and computed tomography (CT) but not TTE was also predictive of PVL. 29 These studies suggest a certain amount of oversizing is indeed necessary to prevent PVL. Indeed, Detaint et al 30 reported that patients with aortic annulus <22 mm by echocardiography had no moderate-severe PVL after TAVR. Although echocardiography is the most widely used method for measuring the annulus, multi-detector computed tomography (MDCT) allows 2 ×∠LVOT-AO + (depth to NCC -10)² ≥ 50, the likelihood of occurrence of significant AR could be predicted with a sensitivity of 85% and a specificity of 87%. n=50
Depth of device in relation to NCC (minimum chance of significant AR corresponding to depth = 9.5 mm)
Depth of the device in relation to LCC (minimum chance of significant AR corresponding to depth = 10.42 mm)
AR indicates aortic regurgitation; AUC, area under the curve; AVR, aortic valve replacement; BPD, balloon postdilation; CI, confidence interval; LCC, left coronary cusp; ∠LVOT-AO, angle of left ventricular outflow tract to ascending aorta; MDCT, multi-detector computed tomography; NCC, Non-coronary cusp; NYHA, New York Heart Association; OR, odds ratio; PVL, paravalvular leak; PVR, paravalvular regurgitation; and TEE, transesophageal echocardiography.
*Area Cover Index (1−Annulus area/Prosthesis nominal area). †Cover Index=(100 × ([prosthesis diameter -TEE annulus diameter]/prosthesis diameter). January 22, 2013
3-dimensional reconstruction of the annulus and multi-planar measurements of annular diameter, area, and circumference. 31 THV oversized by at least 1 mm relative to the mean annular diameter, or by ≥10% of the annular area, as measured by MDCT, have a reduced risk of moderate to severe PVL. 32 The same study suggests that the difference between annular perimeter measurement and THV size by MDCT was a slightly better predictor of PVL when compared with TEE, 32 although this may be partially attributable to differences in the type of measurement obtained (circumference by MDCT versus sagittal diameter by TEE) rather than the imaging modality used. The current TAVR technique systematically oversizes the THV ≈2 to 5 mm larger than the native valve. However, oversizing is not without risks and may cause annular rupture, coronary artery occlusion, and arrhythmias, underscoring the importance of accurately measuring the aortic annulus. Appropriate positioning of the bioprosthesis is essential to preventing PVL but is challenging in the setting of a beating heart and catheter-guided deployment. The incidence of CoreValve dislocation ranged from 3% to 10% depending on the series. 33 Similar results have been reported for the Edwards valve 34, 35 (4% to 11%). Sherif et al 36 set out to identify anatomic predictors of PVL using angiography in patients undergoing TAVR with the CoreValve: the angle of the left ventricular outflow tract to the ascending aorta as well as the depth of the device in relation to the noncoronary cusps were found to be independent predictors of PVL. 36 For all THV, the greater the angle the more likely the device incompletely seals the paravalvular space. Further, if implanted too low, the covered skirt may be situated below the native annulus, allowing blood to regurgitate through the holes of the uncovered portion of the stent frame, whereas high implantation allows blood to flow in the space between prosthesis and annulus. In addition to PVL, malposition and potential valvular dislocation is a serious complication of TAVR, which may cause coronary ischemia, arrhythmias requiring pacemaker implantation, and is associated with excess 30-day mortality (21.5% versus 9.9%). 33 Newer devices in development have an improved ability to reposition the valve during deployment and should reduce the incidence of PVL.
The extent of native aortic valve calcification and its location has been repeatedly shown to be predictive of PVL post-TAVR with both the Edwards and CoreValve THV, 17, 18, [37] [38] [39] [40] [41] because it impairs apposition and complete expansion of the THV by imposing an asymmetrical shape to the valve deployment area. Different studies have quantified calcification of the aortic root using different imaging techniques and scoring systems. The Agatston Score is derived from ECG-gated multislice contrast-enhanced computed tomography and has been used to characterize total valve and individual cusp calcification. 42 High Agatston Score was correlated with higher degrees of PVL as well as the need for repeat maneuvers during implantation. 38, 40, 41 Cusp calcification at the aortic wall was strongly predictive of PVL at the corresponding site. 38 ,39 TEE has also been used to assess aortic root calcification semiquantitatively using an echocardiographic calcification score devised by Corciu et al 18, 37, 43 Application of this score yields results consistent with the MDCT findings, such that valvular calcification and annular size are strongly predictive of PVL as well as the need for additional maneuvers. 18, 37, 43 Newer devices with more flexible cuffs allowing more complete seal over the retained native valve should mitigate this problem.
Clinical characteristics associated, such as male sex, New York Heart Association functional class IV, and no previous aortic valve replacement, were suggested to be predictive of PVL. 6 The Role of Imaging in Assessing Paravalvular Regurgitation
Identifying and accurately characterizing paravalvular regurgitation in prosthetic valves is challenging. The shielding and reverberations of the valvular frame as well as the eccentricity of the jets render accurate localization and quantification of PVL difficult. Echocardiography, both TTE and TEE, angiography, MDCT, as well as MRI are modalities that have been used across studies to characterize PVL (Table 1) .
Intra-Procedural Imaging
TEE is particularly useful for the detection and assessment of acute aortic regurgitation post-TAVR because it can be performed immediately on deployment. 44 Immediately after valve deployment, stent positioning, shape, leaflet motion, and aortic regurgitation can rapidly be assessed with TEE imaging in biplane mode or a single plane short-axis view. For PVL, the short-axis plane of imaging should be just below the valve stent and skirt and just within the left ventricular outflow tract (LVOT); if the imaging plane is above the stent, regurgitation may not be visualized or color flow just above the annulus but contained within the sinuses of Valsalva may be mistaken for regurgitant jets into the left ventricle. Lower cross sections may erroneously view jet spray rather than vena contracta. Confirmation of the severity of AR should always be performed from multiple echocardiographic views. Because of acoustic shadowing of the anterior THV annulus with midesophageal TEE, imaging just below the stent (within the LVOT) avoids most shadowing issues. The deep gastric view also allows imaging of the LVOT without acoustic shadowing. Imaging the entire annulus is mandatory and requires rotating 180 degrees while centered on the valve.
Aortography post-TAVR can provide accurate PVL evaluation and correlate it immediately with the simultaneous TEE evaluation under the same hemodynamic conditions. Hemodynamic data obtained immediately post-TAVR that include measurement of LV end-diastolic pressure and diastolic pressure and compare them with pre-TAVR values can provide additional information about grading the severity of PVL and has recently been shown to be of prognostic value. 
Post-Procedural Imaging
Transthoracic echocardiograms can identify the presence, location, and severity of the PVL and are the most common form of imaging because of availability and low cost. The optimal views for detection of regurgitant jets include the parasternal long-axis, short-axis, the apical long-axis, and the 5-chamber views, although as a result of eccentric jets, off-axis views should also be used to ensure accurate determination of the location and severity of regurgitation. Paravalvular jets usually travel along the natural curvature of the prosthesis-annular interface, thus imaging in multiple planes is necessary. The transthoracic short-axis view offers the best visualization of the true orifice of PVL and helps prevent the overestimation of AR severity, which can occur when relying solely on apical views.
In quantifying PVL, a comprehensive integrated approach must always be used.The American Society of Echocardiography (ASE) criteria for assessing PVL severity by echocardiography have emphasized describing the jet anatomy (ie, location, circumferential extent, and width 46 ; Table 4 ), particularly when visualized by color Doppler in the aortic short-axis view. These criteria have not been validated in post-TAVR patients, and despite the adoption of these recommendations by the VARC (Valve Academic Research Consortium) 47, 48 they have not been uniformly adopted by the different registries and trials. Most commonly, PVL is assessed qualitatively by estimating the proportion of the circumference of the sewing ring occupied by the jet: <10% of the sewing ring suggests mild, 10% to 20% suggests moderate, and >20% suggests severe. 49 Overall aortic regurgitation is classified as absent (0), trace (<I), mild (I), moderate (II), and severe (III or IV).
In addition, quantitative assessments of regurgitant fraction and volume can also be helpful in determining the severity of PVL. These methods rely on the comparison of stroke volumes across the aortic valve and a nonregurgitant valve. Although total stroke volume can be measured by subtracting LV end-systolic volume from end-diastolic volume, the more common method is to calculate the stroke volume across the LVOT.
Three-dimensional echocardiography may become the method of choice for assessing aortic regurgitant volume.
Three-dimensional TTE is an additional tool that can be used to evaluate the severity of PVL. Vena-contracta planimetry by 3-dimensional TTE correlates better with regurgitant volume than vena contracta width with 2-dimensional TTE. 50 Cardiac MRI may be a useful supplement to echocardiography and may be the modality of choice when there is discordance in grading from different echocardiographic windows. Quantified regurgitant volume and fraction by cardiac MRI appears to correlate better with qualitative angiographic evaluation and less with echocardiographic assessment. Qualitative evaluation by echo may underestimate the severity of PVL when compared with quantitative cardiac MRI measurements.
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Percutaneous Approaches to Treat Paravalvular Leak
The pathophysiologic consequences of acute valvular regurgitation occurring after valve deployment as well as the clinical impact of chronic moderate-severe PVL warrant early and effective remediation to avoid conversion to open surgery as well as prevent progression into heart failure. Thus far there are no universally established indications or algorithm for the procedural management of PVL, and the method of choice is related to the severity of regurgitation and center and operator expertise. Treatment, however, does depend on the onset and cause of regurgitation. Acute valvular regurgitation resulting from initial malpositioning of the THV has been remediated successfully by either refolding and reinserting the valve, or repositioning of the valve using the snare technique. Both techniques are possible using the CoreValvebioprosthesis and have been described by Vavouranakis et al 52 as bail-out solutions, given the CoreValve was not designed for repositioning. Utmost importance should be given to correctly placing the THV on the first attempt, because these techniques are not without risk; the valve may embolize, obstruct the coronary ostium, or induce trauma to the aortic wall and subsequent atheroembolization and strokes.
In patients with THV appropriately positioned, incomplete expansion of the bioprosthetic frame is deemed a major cause of PVL, and is routinely mediated with balloon postdilatation in both the self-expandable CoreValve 28, 53 and the balloonexpandable Edwards Valve (Figure 2 ). 17 Success rates have been reproducible, with postdilation regurgitation reduced by ≥1 grade in >70% of patients. 17 Risks of overexpansion include injury to the leaflets, annular rupture, and atrioventricular block. Cerebrovascular events were noted to be significantly increased postdilation, especially in patients with a high burden of valvular calcium. 17 The concern for strokes has mitigated the widespread use of balloon postdilatation.
In cases of suboptimal deployment of the THV and the inability to reposition, valve-in-valve implantation has emerged as an alternative to treat severe PVL. 54 Outcomes data from the Italian CoreValve registry in which 24 patients underwent valve-in-valve are encouraging, showing 100% procedural success and outcomes similar to uneventfully placed valves. 55 The most common reason for redeployment was low positioning of the THV (75% of cases). 55 Hemodynamic performance of the valve-in-valve prosthesis was satisfactory, with no newonset PVL, embolic events, or impingement on the coronary ostia within the 12-month period. 55 Atrioventricular blocks requiring pacing were, however, more common. 55 Limited outcomes data for valve-in-valve with the Edwards-Sapiens valve are available from a smaller series of 5 patients with severe PVL showing similar results. 56 Data from larger series with longer follow-up are necessary to justify the use of valvein-valve in patients with less than severe PVL.
Patients with chronic PVL may present asymptomatically, with significant hemolysis or signs of heart failure. The efficacy of paravalvular defect repair using catheter-delivered occluding devices, such as the Amplatzer vascular plugs, is well-established in post-SAVR patients. [57] [58] [59] The deployment techniques have been extensively described by Rihal et al, 57 who reported outcomes after closure of 141 defects in 115 patients post-SAVR who presented with heart failure (93%) and hemolysis (37%). 57 Successful device deployment rate was 89%, with a total 30-day complication rate of 8.7%. 57 Seventy-two percent of patients were symptom-free at 3 years. 59 Potential complications relate to embolization of the occluders, leading to obstruction of the prosthetic valve leaflets or distally in the iliac arteries. Obstruction of the coronary ostia can occur when para-aortic defects are treated. It is important to note that persistent regurgitation postprocedurally is ominous, with patients having poor survival (30.3%) at 3 years. 57 Occluders have been used successfully in treating PVL post-TAVR (Figure 3) . 60 However, until outcomes from large series of post-TAVR patients undergoing the procedure are available, its efficacy remains unclear in this group of patients with PVL.
Center expertise and the optimization of the TAVR technique should also impact the incidence of PVL. Unbehaun et al, 6 using a modified 3-step procedural strategy of transapical TAVR, yielded a very low incidence of moderate PVL (0.2%) with absolutely no cases of severe PVL. The development of next-generation THV aims to address several procedural challenges in TAVR. 61 New valves, such as the Edwards CENTERA, the JenaValve, Sadra Medical Lotus, and Saint Jude Portico, allow for repositioning and retrieval. Their designs also include innovative mechanisms to minimize PVL, such as anchors or adaptive skirts in the lower part of the prosthesis that conform to irregular surfaces and provide a seal with the aortic annulus.
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Future Directions
Paravalvular regurgitation is common post-TAVR and is an established independent prognostic factor, with even mild PVL appearing to have important negative clinical consequences. However, the risks and impact of PVL can be mitigated by careful preprocedural imaging and device selection, standardization of procedural techniques and imaging, prompt recognition and accurate characterization of acute PVL, and long-term surveillance, prevention, and management of PVL. As the use of TAVR expands to lower risk groups, the need to address PVL through these techniques as well as by the development of THV technology is essential to ensure a favorable risk-benefit ratio for the patient.
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